Synopsys (SNPS) Tests Long Standing Support As Undervaluation Hopes Face A Reality Check

Synopsys stock triggered by a test of long-standing price support

Synopsys (SNPS) has been back in focus after its share price retreated toward a long-tested support zone around US$412 to US$455, an area traders report has held multiple times in recent history.

See our latest analysis for Synopsys.

At a latest share price of US$425.90, Synopsys has eased back toward that support band, with the share price down over the past month and year to date. The 5-year total shareholder return of 53.26% still reflects longer-term gains.

If recent volatility around Synopsys has you thinking about other potential opportunities linked to AI and chips, this could be a good moment to scan 52 AI infrastructure stocks

With Synopsys now trading well below the average analyst price target and also below one internal fair value estimate, the real debate is where fair value sits inside that spread and how far today’s pullback already reflects it.

Most Popular Narrative: 23.9% Undervalued

At a last close of $425.90, the most followed Synopsys narrative anchors fair value around $559.58, leaving a clear gap for investors to assess.

The accelerating complexity and proliferation of AI, high-performance computing, and multi-die/chiplet-based architectures are increasing customer demand for Synopsys' advanced design, verification, and simulation solutions, solidifying its role as a mission-critical partner in next-generation chip and system development. This supports both revenue growth and opportunities for higher-margin recurring licensing.

Read the complete narrative.

Want to see why this narrative supports a much higher fair value for Synopsys? It leans heavily on faster earnings growth, fatter margins, and a richer future profit multiple. The exact assumptions might surprise you.

Result: Fair Value of $559.58 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Synopsys still faces meaningful risks, including tighter export controls affecting China revenue and the execution challenge of integrating Ansys while reshaping its IP business model.

Find out about the key risks to this Synopsys narrative.

Another view on Synopsys valuation

The popular Synopsys narrative leans on earnings growth and analyst targets that point to the stock being 23.9% undervalued. On a simple earnings multiple though, Synopsys trades on a P/E of 105.5x versus 28.9x for the US Software industry and 33.7x for close peers, while the fair ratio estimate is 48.9x. That kind of gap can signal either a premium story or a lot of valuation risk if expectations reset, so which side of that trade do you think you are really on?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed signals around Synopsys leave you uncertain, take a moment to review both sides. Then move quickly to weigh the 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Synopsys?

If Synopsys has sharpened your thinking, do not stop here. Use the Simply Wall Street Screener to spot fresh opportunities that match your style.

• Target potential bargains that pair quality with attractive pricing by checking 44 high quality undervalued stocks before others move first.
• Prioritise resilience and balance sheet strength by reviewing the solid balance sheet and fundamentals stocks screener (48 results) so your next idea is built on firmer footing.
• Get ahead of the crowd by tracking the screener containing 20 high quality undiscovered gems that may not be on most radars yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com